	US 12,064,414 B2
	Stable amorphous Eliglustat premix and process for the preparation thereof
Venkata Nookaraju Sreedharala, Hyderabad (IN); and Vijaya Rajesh Kumar Yelchuri, Hyderabad (IN)
Assigned to AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED., Hyderabad (IN)
Appl. No. 16/956,269
Filed by AIZANT DRUG RESEARCH SOLUTIONS PRIVATE LIMITED., Hyderabad (IN)
PCT Filed Dec. 4, 2018, PCT No. PCT/IN2018/050812 § 371(c)(1), (2) Date Jun. 19, 2020, PCT Pub. No. WO2019/123476, PCT Pub. Date Jun. 27, 2019.
Claims priority of application No. 201741045763 (IN), filed on Dec. 20, 2017.
Prior Publication US 2020/0316025 A1, Oct. 8, 2020
Int. Cl. A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 31/4025 (2006.01); A61K 45/06 (2006.01)

CPC A61K 31/4025 (2013.01) [A61K 9/006 (2013.01); A61K 9/20 (2013.01)]

12 Claims

1. A stable pharmaceutical composition of amorphous Eliglustat which comprises:

i. a stable amorphous Eliglustat premix comprising of Eliglustat or its pharmaceutically acceptable salt with at least one premixing agent, and

ii. at least one stabilizer comprising basic inorganic salts of magnesium, and

iii. optionally, at least one pharmaceutically acceptable excipient, wherein the said premix is free flowing.